Danaher Corp
DHRQ3 2022(DHR Q2 FY2022)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$619.4M
AI Revenue (Q)
$77.5M
Total Revenue (Q)
$7.8B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q2 FY2022 (three-month period ended July 1, 2022). Total sales $7,751M across four segments: Life Sciences $3,967M, Diagnostics $2,561M, Biotechnology (not yet split out), Environmental & Applied Solutions $1,223M. DHR does not disclose any AI-specific revenue. None of its segments are labeled as AI. The filings contain zero mentions of artificial intelligence, machine learning, or AI products. DHR sells scientific instruments, reagents, consumables, and diagnostic equipment (Beckman Coulter, Leica, SCIEX, Cytiva, Cepheid, Pall). Some instruments may embed basic algorithms for image analysis or pattern recognition (e.g., Leica digital pathology, Beckman flow cytometry), but these are sold as complete instruments, not AI solutions. Conservative estimate: ~1% reflects minimal embedded algorithmic content in instrument software. Math: ~$78M estimated AI-adjacent / $7,751M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $7,751 [three-month period ended July 1, 2022]
10-Q Q2 FY2022, Consolidated Condensed Statements of Earnings
Life Sciences $3,967; Diagnostics $2,561; Environmental & Applied Solutions $1,223 [three-month period ended July 1, 2022]
10-Q Q2 FY2022, Note 6 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Life Sciences instrumentsDiagnostics instrumentsBiotechnology consumablesEnvironmental & Applied Solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix